Neurocrine Biosciences, Inc announced the launch of a new sprinkle formulation of INGREZZA capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the...
Neurocrine Biosciences, Inc., a leading neuroscience-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application...
Neurocrine Biosciences, Inc., a leading neuroscience-focused biopharmaceutical company, today announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT™...
Neurocrine Biosciences, Inc. announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the...
